Revolutionizing Continuous Blood Pressure Monitoring with Motion-Correction Technology
Cambridge, MA. – December 3, 2024 Dynocardia has been awarded a $1 million grant by the National Science Foundation (NSF) to enhance its innovative computer vision-based motion-artifact mitigation technology. This funding will accelerate the development of the ViTrack® continuous non-invasive blood pressure (cNIBP) monitor, enabling real-time, accurate measurements of blood pressure and vital signs in diverse environments, including ambulances, hospitals, and homes. ViTrack’s cuff-less design employs advanced optomechanical sensors and computer vision to overcome challenges posed by patient movement, setting a new standard for continuous health monitoring.
Read the full press releaseDynocardia's Direct Continuous Blood Pressure Monitoring Technology Receives Grant from NIH's Commercialization Readiness Pilot Program
CAMBRIDGE, Mass., Oct. 10, 2024 /PRNewswire/ -- The National Heart, Lung, and Blood Institute (NHLBI), one of the institutes that comprise the National Institutes of Health (NIH), has awarded Dynocardia, a medical technology company that is pioneering a new modality in blood pressure (BP) monitoring, a $500,000 grant under its Commercial Readiness Pilot (CRP) Program.
Read the full press releaseJordan Parker-Ashe and Victoria Gonzalez-Canalle represented Dynocardia at the 2024 Engineering for Women's Health conference hosted by Northeastern University.
Our biomedical engineers Jordan Parker-Ashe and Victoria Gonzalez-Canalle represented Dynocardia at the 2024 Engineering for Women's Health conference hosted by Northeastern University. Scientists and professionals across the life sciences, medicine, and engineering disciplines gathered to share breakthrough research and lay the groundwork for tomorrow's innovations, as well as forge new connections and learn from each other. This experience was especially meaningful, as Dynocardia is conducting ongoing clinical trials involved in maternal health.
Revolutionizing Healthcare Through Cutting-Edge Research and Technology
Dynocardia have participated in the prestigious MIT Madrid Symposium, where our cutting-edge research and innovative technology took center stage. Our breakthrough solutions, designed to revolutionize healthcare, were spotlighted as we continue to push the boundaries of medical science.
MIT ILP